Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

By afschroeder • December 19, 2025

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim G, Kim C, Chon HJ. Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Liver Cancer. 2025 Nov 18. doi: 10.1159/000549565. Epub ahead of print. PMID: 41409410; PMCID: PMC12707966.

Tags: Atezolizumab plus bevacizumab, circulating tumor DNA, Concordance, Hematology/Oncology, Hepatocellular carcinoma, Prognostic marker, Publications

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, Hu R, Tang C, Liu Q, Zeng W, Yeh A, Melehy A, Tran[...]

Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

López JCV, Ho A, Hughes KS, Bardia A, Vidula N. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to[...]

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton[...]